Parkinson’s Active Immunotherapy Medicine Phase 1 Study Positive Results Published

[Farooqji]

The Phase 1 successfully met its primary outcome measures, demonstrating that UB-312 was generally well-tolerated and induced anti-aggregated α-synuclein (αSyn) antibody responses in healthy volunteers and PD patients. Specifically, 12 of 13 PD patients who completed dosing developed anti-αSyn antibodies

precisionvaccinations.com/2...

[Farooqji]

A Potential Parkinson’s Treatment Has Promising Results

time.com/6883054/parkinsons...

[park_bear]

Results published in Figure 3, charts E and F, of this study: nature.com/articles/s41591-...

UPDRS part two got better but part 3 got worse, net result they canceled each other out. Small sample but this was a 44 week study, so I personally do not find this result particularly encouraging.

[Awyn in reply to park_bear]

I agree. This path of study has a long way to go.

[Awyn]

While the promise of a preventative vaccine may appeal to many people, and I am happy to see this path of study targets an Alpha-synuclein protein (aSyn) solution, I am more inclined to hope Parkinson's (PD) science will focus its resources and successfully advance a targeted protein inhibitor biologic.

You are probably already familiar with this 2020 study, which illustrates the complicated process PD is up against regarding misfolded aSyn protein.

"Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers" (Nov 2020) ncbi.nlm.nih.gov/pmc/articl...

There are several exciting approaches to dealing with misfolded aSyn protein: molecular chaperones, small molecule inhibitors, HYPE protein, AMPylation, Sigma-2 receptor compounds, as well as Immunotherapy, like this vaccine study.

Of these, the small molecule inhibitor is exciting to contemplate for those already experiencing PD symptoms. What if a protein inhibitor could substantially clear while preventing misfolded aSyn in a riddled PD brain?

My husband has been implementing integrative therapies and lifestyle practices in addition to prescribed functional medicine to arrest/reverse his two diagnoses... Chronic Lymphocytic Leukemia (CLL) and Parkinson's.

Regarding CLL, an intense biological protein inhibitor medication has been a part of his daily routine for the past seven years (he was diagnosed in 2012 and didn't become a candidate for this breakthrough treatment until his condition had seriously debilitated).

This daily biologic pill is a protein inhibitor ... a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's Tyrosine Kinase. It is not Immunotherapy, although it has a similar outcome, realigning the impaired body system to function correctly once the disease is arrested. Over this past year, my husband's bloodwork and exams have been exceptional, and last month, his oncologist stopped the treatment and officially pronounced my husband in "remission." It's been a long, yet positive, uphill trek to get to this moment.

The results of CLL and other cancers' protein inhibitors are cutting-edge miraculous advances, and we are optimistic as we learn that PD science is stepping in a potentially similar direction....at the least, beginning to focus on eliminating the negative protein factor of the disease.

"A small molecule 20C from Gastrodia elata inhibits α-synuclein aggregation and prevents progression of Parkinson's disease" (Sept 2023) nature.com/articles/s41419-...

"Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment" (January 2023). nature.com/articles/s41401-...

"Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease" (March 2023). mdpi.com/1999-4923/15/3/839

We have questioned potential B-cell implications between PD and CLL for some time. Cytokine implications. Immunology Microbiome. Blood-brain Barrier. Neurotoxicity. Oxidative stress. Toxicity. Potential Environmental Factors. We have found several commonalities as he battles both diseases, yet very little in the way of studies explicitly linking the two conditions.

Meanwhile, clearing away the "globs" (that's our choice of word) in the substantia nigra basal ganglia part of the brain that produces dopamine, attempting to awaken the zombie neurons that have succumbed to the misfolded aSyn "globs," trying to reduce inflammation (in particular neuroinflammatory responses) and seeking strategies that work on freeing the glial cell signal pathways that deliver dopamine to other parts of the brain, is a mindful, mind-boggling, mind-blowing, daily pursuit.

Glutathione, Hydrogen water, organic whole food Mediterranean diet, keeping carbs down, B12, B1, D3, zinc, Lutein, Magnesium LThreonate, Yoga, fast-walking, gardening, playing guitar, performing with his band, playing with our toddler granddaughter and finding ways to lessen the daily stresses of "life, the universe, and everything" are just a FEW things he practices.

Despite its horrible dental side effects (our previously posted saga), he also takes a minimum dose of C/L. He will likely continue to do so until a substantial breakthrough therapy improves dopamine production and dissemination.